Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/BID_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/BID_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/BID_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/BID_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000698410 | Esophagus | HGIN | ER-nucleus signaling pathway | 19/2587 | 46/18723 | 4.28e-06 | 1.41e-04 | 19 |
GO:000863720 | Esophagus | HGIN | apoptotic mitochondrial changes | 33/2587 | 107/18723 | 4.32e-06 | 1.42e-04 | 33 |
GO:000734610 | Esophagus | HGIN | regulation of mitotic cell cycle | 98/2587 | 457/18723 | 4.39e-06 | 1.42e-04 | 98 |
GO:007099727 | Esophagus | HGIN | neuron death | 81/2587 | 361/18723 | 5.01e-06 | 1.61e-04 | 81 |
GO:200105620 | Esophagus | HGIN | positive regulation of cysteine-type endopeptidase activity | 41/2587 | 148/18723 | 6.65e-06 | 2.07e-04 | 41 |
GO:001095020 | Esophagus | HGIN | positive regulation of endopeptidase activity | 47/2587 | 179/18723 | 7.23e-06 | 2.20e-04 | 47 |
GO:000183618 | Esophagus | HGIN | release of cytochrome c from mitochondria | 21/2587 | 59/18723 | 2.14e-05 | 5.72e-04 | 21 |
GO:00447729 | Esophagus | HGIN | mitotic cell cycle phase transition | 89/2587 | 424/18723 | 2.80e-05 | 7.21e-04 | 89 |
GO:00901998 | Esophagus | HGIN | regulation of release of cytochrome c from mitochondria | 18/2587 | 48/18723 | 3.67e-05 | 9.22e-04 | 18 |
GO:200102019 | Esophagus | HGIN | regulation of response to DNA damage stimulus | 52/2587 | 219/18723 | 5.00e-05 | 1.19e-03 | 52 |
GO:19019906 | Esophagus | HGIN | regulation of mitotic cell cycle phase transition | 65/2587 | 299/18723 | 1.12e-04 | 2.36e-03 | 65 |
GO:000863020 | Esophagus | HGIN | intrinsic apoptotic signaling pathway in response to DNA damage | 28/2587 | 99/18723 | 1.24e-04 | 2.54e-03 | 28 |
GO:20000456 | Esophagus | HGIN | regulation of G1/S transition of mitotic cell cycle | 36/2587 | 142/18723 | 1.74e-04 | 3.35e-03 | 36 |
GO:00000827 | Esophagus | HGIN | G1/S transition of mitotic cell cycle | 48/2587 | 214/18723 | 3.97e-04 | 6.07e-03 | 48 |
GO:000862518 | Esophagus | HGIN | extrinsic apoptotic signaling pathway via death domain receptors | 23/2587 | 82/18723 | 5.47e-04 | 7.73e-03 | 23 |
GO:00448437 | Esophagus | HGIN | cell cycle G1/S phase transition | 52/2587 | 241/18723 | 6.19e-04 | 8.58e-03 | 52 |
GO:200123626 | Esophagus | HGIN | regulation of extrinsic apoptotic signaling pathway | 36/2587 | 151/18723 | 6.20e-04 | 8.58e-03 | 36 |
GO:19028065 | Esophagus | HGIN | regulation of cell cycle G1/S phase transition | 39/2587 | 168/18723 | 6.60e-04 | 9.03e-03 | 39 |
GO:005140219 | Esophagus | HGIN | neuron apoptotic process | 52/2587 | 246/18723 | 1.01e-03 | 1.26e-02 | 52 |
GO:00427708 | Esophagus | HGIN | signal transduction in response to DNA damage | 39/2587 | 172/18723 | 1.07e-03 | 1.32e-02 | 39 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501430 | Esophagus | HGIN | Amyotrophic lateral sclerosis | 140/1383 | 364/8465 | 2.13e-25 | 1.16e-23 | 9.19e-24 | 140 |
hsa0502230 | Esophagus | HGIN | Pathways of neurodegeneration - multiple diseases | 153/1383 | 476/8465 | 1.22e-18 | 4.41e-17 | 3.50e-17 | 153 |
hsa0501030 | Esophagus | HGIN | Alzheimer disease | 130/1383 | 384/8465 | 5.26e-18 | 1.71e-16 | 1.36e-16 | 130 |
hsa0493230 | Esophagus | HGIN | Non-alcoholic fatty liver disease | 66/1383 | 155/8465 | 5.21e-15 | 1.21e-13 | 9.64e-14 | 66 |
hsa0516930 | Esophagus | HGIN | Epstein-Barr virus infection | 55/1383 | 202/8465 | 5.13e-05 | 6.19e-04 | 4.92e-04 | 55 |
hsa0516730 | Esophagus | HGIN | Kaposi sarcoma-associated herpesvirus infection | 51/1383 | 194/8465 | 2.46e-04 | 2.69e-03 | 2.14e-03 | 51 |
hsa0421020 | Esophagus | HGIN | Apoptosis | 36/1383 | 136/8465 | 1.67e-03 | 1.52e-02 | 1.20e-02 | 36 |
hsa0517029 | Esophagus | HGIN | Human immunodeficiency virus 1 infection | 51/1383 | 212/8465 | 2.16e-03 | 1.90e-02 | 1.51e-02 | 51 |
hsa0541739 | Esophagus | HGIN | Lipid and atherosclerosis | 51/1383 | 215/8465 | 2.95e-03 | 2.41e-02 | 1.91e-02 | 51 |
hsa0516420 | Esophagus | HGIN | Influenza A | 42/1383 | 171/8465 | 3.41e-03 | 2.54e-02 | 2.02e-02 | 42 |
hsa0411510 | Esophagus | HGIN | p53 signaling pathway | 21/1383 | 74/8465 | 6.25e-03 | 4.25e-02 | 3.37e-02 | 21 |
hsa0516330 | Esophagus | HGIN | Human cytomegalovirus infection | 51/1383 | 225/8465 | 7.67e-03 | 4.63e-02 | 3.68e-02 | 51 |
hsa05014113 | Esophagus | HGIN | Amyotrophic lateral sclerosis | 140/1383 | 364/8465 | 2.13e-25 | 1.16e-23 | 9.19e-24 | 140 |
hsa05022113 | Esophagus | HGIN | Pathways of neurodegeneration - multiple diseases | 153/1383 | 476/8465 | 1.22e-18 | 4.41e-17 | 3.50e-17 | 153 |
hsa05010113 | Esophagus | HGIN | Alzheimer disease | 130/1383 | 384/8465 | 5.26e-18 | 1.71e-16 | 1.36e-16 | 130 |
hsa04932113 | Esophagus | HGIN | Non-alcoholic fatty liver disease | 66/1383 | 155/8465 | 5.21e-15 | 1.21e-13 | 9.64e-14 | 66 |
hsa05169114 | Esophagus | HGIN | Epstein-Barr virus infection | 55/1383 | 202/8465 | 5.13e-05 | 6.19e-04 | 4.92e-04 | 55 |
hsa05167114 | Esophagus | HGIN | Kaposi sarcoma-associated herpesvirus infection | 51/1383 | 194/8465 | 2.46e-04 | 2.69e-03 | 2.14e-03 | 51 |
hsa04210110 | Esophagus | HGIN | Apoptosis | 36/1383 | 136/8465 | 1.67e-03 | 1.52e-02 | 1.20e-02 | 36 |
hsa05170112 | Esophagus | HGIN | Human immunodeficiency virus 1 infection | 51/1383 | 212/8465 | 2.16e-03 | 1.90e-02 | 1.51e-02 | 51 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BID | SNV | Missense_Mutation | | c.710N>A | p.Arg237Lys | p.R237K | P55957 | protein_coding | deleterious(0.01) | benign(0.368) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
BID | SNV | Missense_Mutation | | c.641N>A | p.Arg214His | p.R214H | P55957 | protein_coding | tolerated(0.26) | benign(0.141) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
BID | SNV | Missense_Mutation | | c.178N>A | p.Glu60Lys | p.E60K | P55957 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BID | insertion | Frame_Shift_Ins | novel | c.385_386insGAATCGGATTAAGGACATCA | p.Ile129ArgfsTer31 | p.I129Rfs*31 | P55957 | protein_coding | | | TCGA-AR-A1AQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
BID | deletion | In_Frame_Del | rs759487323 | c.608_619delAGAAGGTGGCCA | p.Lys203_Ala206del | p.K203_A206del | P55957 | protein_coding | | | TCGA-B6-A0X1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
BID | SNV | Missense_Mutation | | c.146N>A | p.Cys49Tyr | p.C49Y | P55957 | protein_coding | deleterious(0.03) | benign(0.001) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BID | SNV | Missense_Mutation | rs747016844 | c.265G>A | p.Glu89Lys | p.E89K | P55957 | protein_coding | tolerated(0.09) | benign(0.134) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
BID | SNV | Missense_Mutation | rs547322681 | c.626C>T | p.Thr209Met | p.T209M | P55957 | protein_coding | tolerated(0.35) | benign(0.23) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
BID | SNV | Missense_Mutation | novel | c.350G>T | p.Arg117Ile | p.R117I | P55957 | protein_coding | tolerated(0.12) | benign(0.26) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BID | SNV | Missense_Mutation | rs575351241 | c.446N>T | p.Pro149Leu | p.P149L | P55957 | protein_coding | tolerated(0.17) | benign(0.068) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |